Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR6676)
Name
Rifaximin alpha
Disease Hepatic fibrosis/cirrhosis [ICD-11: DB93] Phase 4 [1]
DrugBank ID
DB01220
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Lactoferrin + Arabinogalactan     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Retrospective observational survey study
                    Experimental
                    Result(s)
Combination therapy with cyclic rifaximin-Alpha and continuous arabinogalactan combined with lactoferrin are effective in SUDD treatment in terms of symptom resolution, bowel movement normalization, prevention of recurrences with very good patient's compliance.
Target and Pathway
Target(s) Bacterial DNA-directed RNA polymerase beta (Bact rpoB)  Molecule Info  [3]
Pregnane X receptor (NR1I2)  Molecule Info  [4]
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity Click to Show/Hide
2 Nuclear Receptors Meta-Pathway
3 Pregnane X Receptor pathway
4 Drug Induction of Bile Acid Pathway
5 Nuclear Receptors
References
Reference 1 ClinicalTrials.gov (NCT02019784) Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
Reference 2 Combined therapy: rifaximin-Alpha and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease. Pol Przegl Chir. 2020 Apr 7;92(2):22-28.
Reference 3 Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58.
Reference 4 Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007 Jul;322(1):391-8.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China